SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Celsion (CLN AMEX) was CELN

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: TEDennis who wrote (791)11/2/2001 9:05:33 AM
From: TEDennis  Read Replies (2) of 966
 
Thursday November 1, 9:38 am Eastern Time

Press Release

SOURCE: Celsion Corporation

Celsion Profiled in Updated National Financial Network Report

COLUMBIA, Md., Nov. 1 /PRNewswire/ -- CELSION CORPORATION (Amex: CLN - news) today announced that National Financial Network, a division of National Financial Communications Corp. (NFC) of Needham, Massachusetts, has issued an updated corporate profile on the Company. Interested parties can access the updated report at www.nfnonline.com/cln/report.html.

Geoffrey J. Eiten, president of National Financial Communications, stated, ``Celsion is at a critical juncture on the path to commercialization of its non-invasive treatment of Benign Prostatic Hyperplasia (BPH). As the Company approaches the end of pivotal Phase II clinical trials of the BPH treatment system and prepare to bring it to market, it is important to keep the financial community abreast of breaking developments. To that end, we have updated our corporate profile of the Company, to reflect recent events.''

About Celsion: Celsion Corporation, based in Columbia, Maryland, is a biomedical research and development company dedicated to commercializing cancer drug and treatment systems based on its patented focused heat technology platform. The Company is currently conducting two pivotal Phase II clinical trials on treatment systems for breast cancer and BPH. The Company has also developed temperature-sensitive drug and gene delivery technology platforms capable of localizing and concentrating therapeutic drug payloads within targeted tumors, also using focused heat energy. Celsion has research, license or commercialization agreements with leading institutions such as Duke University Medical Center, Massachusetts Institute of Technology, Harbor UCLA Medical Center, the University of California at San Francisco, the Center for Breast Surgery at Columbia Hospital in Florida, Montefiore Medical Center, Memorial Sloan Kettering Cancer Center in New York and Duke University. For more information on Celsion, visit our website: celsion.com.

About National Financial Communications: National Financial Network is a division of National Financial Communications Corp. (NFC). Headquartered in Needham, Massachusetts, NFC is a full-service financial communications and investor relations firm that specializes in small-cap companies. In addition, NFC operates from four independent affiliate offices in California, Oregon, Colorado and Florida. The Company offers its services to companies listed on all major exchanges in addition to the over-the-counter markets, and is a past recipient of the Bulldog Award for Excellence in Media Relations and Publicity. For more information on NFC, visit www.nationalfc.com.

National Financial Network, a division of National Financial Communications corporation, serves as special advisor to the featured Company and has received fees for services. This is not an offer to buy or sell securities. Information or opinions in this report are presented solely for informative purposes, and are not intended nor should they be construed as investment advice.

Forward-looking statements in this release are made pursuant to the ``safe harbor'' provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; possible changes in cost and timing of development and testing, capital structure, and other financial items; changes in approaches to medical treatment; introduction of new products by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.

For Further Information Contact:
Tony Deasey
Celsion Corporation
410.290.5390
tony@celsion.com

Geoffrey Eiten
National Financial Network
888.399.7541 (ext. 613)
geiten@nfnonline.com

SOURCE: Celsion Corporation

biz.yahoo.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext